deltatrials
Completed PHASE2/PHASE3 NCT00180011

Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

Sponsor: DiMango, Emily, M.D.

Conditions Asthma
Interventions Omalizumab
Updated 6 times since 2017 Last updated: Feb 27, 2012 Started: Sep 30, 2005 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

Listed as NCT00180011, this PHASE2/PHASE3 trial focuses on Asthma and remains completed. Sponsored by DiMango, Emily, M.D., it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • DiMango, Emily, M.D.
  • Genentech, Inc.
  • Novartis
Data source: DiMango, Emily, M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States